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     The purpose of this research paper is to study, analyze, and characterize antibiotic 
resistance in both the theoretical and investigative contexts. After an in-depth 
examination of the literature and previous research investigating the definition, origin, 
affected organisms, and proposed coping mechanisms related to antibiotic resistance, a 
research plan was organized and executed.  
      The organism Methicillin Resistant Staphylococcus aureus (MRSA) was selected as 
the focus of study because of abundant current research and regulated monitoring of this 
organism in healthcare organizations. Data about the incidence rates of MRSA in the 
United States was collected from reports disseminated by the Center for Disease Control 
(CDC).  Information about the number of healthcare-associated infections in the state of 
New Hampshire was provided by the State Department of Health, and two hospitals 
contacted offered information on the number of MRSA isolates recorded.   
     The national data revealed that the overall trend is a significant decrease in the number 
of cases of MRSA.  Statewide data collection also showed reduced numbers of 
healthcare-associated infections.  The data from individual hospitals reveal steady, very 
low grade infection rates.  
     The major conclusion of this research endeavor is that current infection control plans 
and procedures, including standard and specialized precautions and innovative and 
sometimes aggressive treatment plans, have a positive effect on infection rates.  Though 
MRSA and other antibiotic-resistant infections remain an ever-looming threat, human 
innovation and effort can still bring one of the most major medical concerns of this era 




     In any healthcare setting, a significant amount of time, energy and money is spent on 
infection control studies and procedures.  There is much talk of healthcare-acquired 
infections, categorization of them, and stringent procedures and regulations regarding 
their control. One of the primary concerns of infection control departments is the rise of 
antibiotic-resistant bacterial infections; they have become a ubiquitous problem both in 
the healthcare setting and in the general population. Their causes emerge from natural 
selection and mutation and are strengthened by human misunderstanding of the purpose 
and function of antibiotics. Hope for control of this situation lies in public health 
campaigns, standardized infection control precautions, and research and development of 
new methods of prevention and treatment.  
     One of the most well-known antibiotic resistant infections is Methicillin Resistant 
Staphylococcus aureus, commonly referred to as MRSA.  Hospitals around the country 
routinely screen for the presence of this bacterium and characterize its many strains.  The 
purpose of this research endeavor is to explore the history and mechanisms of antibiotic 
resistance, to collect and process national and local records of cases of MRSA, and to 
study and evaluate methods of control and response to this threat.  
     The research was performed in two parts:  part one scrutinized the scientific literature 
to discover the origin of antibiotic resistance, mechanisms of resistance, and the species 
of most concern.  Inquiry into current response and methods of control was also 
performed.   
     As MRSA is an organism of highest interest, the second part involved data collection 
on national, state, and individual hospital levels regarding number of cases of MRSA and 
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its significance in terms of healthcare-associated infection rates.  National data on rates of 
MRSA infection were collected and analyzed to provide a frame of reference and to 
emphasize the significance of this topic and its relation to all people.  Data from the state 
of New Hampshire's Division of Health and Human Services was recorded to form a 
platform of comparison to the national data.  Individual seacoast area hospitals were 
contacted as a function of geographic interest to further explore the climate of antibiotic 
resistance in the immediate area.  Six Southern New Hampshire hospitals were contacted 
and records of infection rates were requested; any available data offered was accepted 
and names of contributing hospitals were removed from analysis to prevent any 
implication of bias.  Two hospitals agreed to participate under these conditions, and the 
rest declined, citing restrictions on the release of data collected for internal surveillance.                                           
All information provided was analyzed in the context of discovering the true prevalence 













III. Background Research 
1. Defining Antibiotic Resistance 
     In the 1940’s, a brand new drug was introduced that held high promise for a disease-
free world.  Antibiotics, originally discovered by Alexander Fleming in 1928, were the 
cure to common infections that in those days killed (Hani.)  Their widespread use caught 
on quickly, and by the 1950’s, an unsettling trend developed.  Certain bacteria which had 
been effectively treated by penicillin were no longer susceptible to the drug.  This trend 
was described as antibiotic resistance, the loss of sensitivity of a microorganism to an 
antimicrobial drug (“Antimicrobial Resistance”,WHO).  Bacteria reproduce quickly and 
therefore, have the ability to change rapidly and to reduce the effectiveness of the drugs 
designed to stop or slow their growth.  They then pass on those genes to future 
generations, propagating the resistance (“About Antimicrobial Resistance”, CDC.) 
     Antibiotic resistance is now a worldwide concern that has arisen from long-term and 
widespread use of antibiotics.  The World Health Organization has outlined some of the 
major causes of antimicrobial resistance.  On a global level, the rise in antibiotic-resistant 
microorganisms is due to a lack of commitment to comprehensive response to disease, 
poor accountability within communities about antibiotic use, negligible surveillance, 
inadequate quality assurance for all areas of the world, inappropriate use of medicines, 
poor infection control, and insufficient research and development of new drugs 
(“Antimicrobial Resistance”, WHO).  In the United States, the largest contributors to 
antimicrobial resistance are inappropriate use of antibiotics, such as taking them when 
they are not needed (for prevention of infection or to treat viral illness) or failing to 
complete a course of antibiotics as prescribed, which selects for resistant organisms.  In 
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addition, antibiotic use is heavier in hospitals, as doctors may prescribe antibiotics before 
a diagnosis is made to prevent an infection from reaching crisis level in a patient before 
cultures can be completed (“Antimicrobial (Drug) Resistance: Causes”).  This creates a 
centralized environment in which resistance can arise and proliferate.   
     This increasing trend is problematic because infection with resistant organisms results 
in longer hospital stays, more expensive treatments and higher risk of death.  Second- or 
third-line antibiotics are frequently used, which may have more side effects and higher 
toxicity (“About Antimicrobial Resistance”, CDC.)  Worldwide, antibiotic resistance 
reduces the control of infectious diseases, meaning that resistant bacteria may be spread 
more easily.  With reduced disease control, major progress that has been made in medical 
technology is jeopardized.  For example, surgery, organ transplantation, and cancer 
treatments are riskier procedures because it leaves people more susceptible to infection 
(“Antimicrobial Resistance”, WHO.)  In fact, the emergence of bacteria that is resistant to 
all available antibiotics, sometimes referred to as “superbugs”, threatens all technology in 












2.  Mechanisms 
 
     In order to understand how bacteria evade the influence of antibiotic drugs, it is 
important to know how antibiotics work.  Antibiotics work to either kill bacteria outright 
or to hamper growth to the point where the human immune system can eliminate what is 
left.  To kill bacteria, an antibiotic must damage the cell wall or vital organelles.  To 
inhibit growth, an antibiotic must interfere with protein production, DNA replication, or 
cellular metabolism (Goering 479.)   
     Many classes of antibiotics are defined by the way in which they attack bacterial cells. 
Penicillins and other β-lactams such as penicillin derivatives and cephalosporins, kill 
bacteria by binding to penicillin-binding proteins and inhibiting an enzyme involved in 
the cross-linking of peptidoglycan in Gram-positive organisms, creating gaps in the cell 
wall (Goering 485.)  Vancomycin and other glycopeptide antibiotics also attack 
peptidoglycan, but instead it binds to D-alanine-D-alanine chains of growing 
peptidoglycan to prevent cross-linking (Goering 489, Gilroy, “Discovery”.)  
     The cytoplasmic membrane of bacterial cells is also a target for antimicrobial drugs. 
Polymyxins, though only used as oral antibiotics in rare occasions, break down the 
phospholipid bilayer structure of bacterial membranes (Goering 502.)  Also, Lipopeptides 
such as Daptomycin depolarize the membrane, preventing the synthesis of ATP and 
absorption of nutrients in the cell.  It is currently used against resistant organisms such as 
Methicillin-resistant Staphylococci and Vancomycin-resistant Enterococci, and shows 
little evidence that organism are developing resistance to it (Goering 502.) 
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     Other mechanisms of bacterial inhibition include binding to the 30s ribosomes, 
blocking formylmethionyl-transfer RNA or aminoacyl transfer RNA from approaching 
the ribosome and beginning translation of RNA into protein.  This is the mode of 
operation of Aminoglycosides such as gentamicin or streptomycin and Tetracyclines 
(Goering 491-492.)  Translation can also be stopped at the 50s ribosomal subunit by the 
Macrolide antibiotics such as azithromycin and erythromycin, lincosamides such as 
clindamycin, streptogramins, and oxazolidinones.  The drugs bind to the 23s ribosomal 
RNA, preventing transfer RNA from being released from the ribosome (Goering 496.)  
     Nucleic acid can also be a target for antimicrobial treatment, and it can be attacked in 
different ways.  Replication is targeted by Fluoroquinolones (ciprofloxacin, levofloxacin, 
etc.) by preventing DNA gyrase from regulating the supercoiling of DNA at the site of 
the replication fork (Goering 498).  Rifamycins such as Rifampin also attack nucleic acid 
by binding RNA polymerase to block transcription (Goering 499.)  Another old class of 
drugs making a resurgence in infection treatment are the Sulfonamides, which prevent the 
synthesis of nucleic acids by interfering with the synthesis of tetrahydrofolic acid, a 
critical part of the nucleic acid bases.  The drugs provide competitive inhibition in the 
folate synthesis pathway’s enzyme dihydropteroate synthetase (DHPS) (Goering 500.) 
Trimethoprim is a drug commonly used with the sulfonamides to combat resistance, as it 
also inhibits folate synthesis but stops dihydrofolate reductase closer to the end of the 
pathway (Goering 501.)   
     A revolutionary new study performed by MIT and Boston University in 2007 resulted 
in a major breakthrough in the way that antibiotic function is viewed.  James Collins, BU 
biomedical engineering professor and Graham Walker, MIT biology professor, proved 
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that β-lactams, amioglycosides, and quinolones all produce hydroxyl radicals that are the 
origin of their antibiotic activity.  Hydroxyl radicals are extremely reactive molecules that 
will oxidize proteins, lipids, and DNA upon contact.  In particular, the radicals damage 
guanine in DNA, activating a repair enzyme called DinB, which incorporates the altered 
guanine and base-pairs it with both cytosine and adenine in new DNA strands.  As 
pairing guanine with adenine is incorrect, this produces defective DNA that cannot 
encode the proteins to make a successful living cell.  If the oxidized guanine actually 
makes it into mRNA, as can happen with aminoglycoside antibiotics, the proteins 
produced work incorrectly and make more hydroxyl radicals to do more damage.  In 
addition, more repair enzymes called MutY and MutM excise DNA for removal of 
oxidized guanine and repair.  With high incorporation of defective guanine, there may be 
so many cuts in the DNA that both strands break, providing another means to destroy the 
bacteria’s DNA (Trafton.)  
     The frequency with which reports of antibiotic-resistant infections in hospitals and 
increasingly within our own communities are heard on the news begs the question of how 
this could happen.  The production of enzymes that inactivate antimicrobial drugs, 
alteration of binding sites that results in reduced reactivity with drugs, changes in 
pathways to the target sites to prevent drugs from accessing their targets, and the 
evolution of efflux pumps to drive antimicrobials out of cells (“Antimicrobial (Drug) 
Resistance: Gonorrheae”) are the basic mechanisms which all strains of bacteria have 
utilized (Goering 486-502.)  Their development may be shared or the result of random 
mutation, and specific mechanisms may vary from organism to organism, or even strain 
to strain.   
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       Essentially since the first use of antibiotics, bacteria have been adapting to enhance 
their survival.  The first mechanism of resistance to β-lactams was the insertion of a gene 
known as mecA, which codes for an extra penicillin-binding protein that does not actually 
bind penicillin and therefore, will continue to synthesize functional peptidoglycan.  
Bacteria have also begun to produce enzymes called Beta-lactamases, which break down 
the beta-lactam ring and prevent the antibiotic from having any effect.  Gram-negative 
cells have even developed resistance mechanisms, despite the fact that they are not the 
primary target of beta-lactams.  Because Gram-negative cells lack the thick 
peptidoglycan layer of Gram-positive cells, the drug must filter through porins in the cell 
membrane to access the penicillin-binding proteins.  Mutations that decrease the 
permeability of the porins prevent the drug from filtering through, and may disable non-
beta-lactams that use the same mechanism as well (Goering 486.) 
     The latter of the last three mechanisms may account for Gram-negative bacteria’s 
widespread resistance to the glycopeptides antibiotics.  They may also have polypeptides 
ending in D-alanine-D-lactate or D-alanine-D-serine instead of the D-alanine-D-alanine 
that is required for glycopeptide binding.  The genes responsible for this mutation have 
been found in studies of Vancomycin-resistant Enterococci.  The genes are titled vanA, 
vanB,and vanD and encode for the abovementioned D-alanine-D-lactate.  The VanA and 
vanB genes have been tracked to transposons and are of particular interest because of the 
easily communicable nature of transposon DNA.  The vanA gene has already been found 
on plasmids that have inferred vancomycin resistance to strains of Staphylococcus aureus 
(Goering 489-490.)  
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     Transposons are also responsible for rising resistance to aminoglycosides and 
tetracyclines.  In aminoglycosides, mutation changes the 30s ribosome to prevent the 
antibiotic from binding.  More significantly, transposons carry genes that encode 
enzymes which react with the drug, changing it to an inert form.  For tetracyclines, 
transposons transfer genes for an efflux pump; when tetracycline is present in a cell, 
different membrane proteins are produced which pump the drug out of cells (Goering 
494-495.) 
     Plasmids are easily transmissible pieces of DNA and are, therefore, a large factor in 
resistance.  In macrolide-resistant cells, plasmids contain genes for an efflux pump 
similar to the one seen in tetracycline-resistant bacteria.  They may also transmit the erm 
gene for a methylase enzyme which methylates two adenines in the 23S rRNA of the 50S 
ribosomal subunit and discourages its binding to macrolides.  Bacteria also feature 
plasmid-encoded resistance to the sulfa drugs.  The plasmid leads to the production of 
altered enzymes which decreases the cell’s affinity for the drug (Goering 496-501.) 
      In some cases, neither plasmid nor transposon-mediated resistance is documented, 
and traditional chromosomal resistance is documented.  As chromosomal resistance can 
only be transferred generationally, it is not an ideal mechanism, but it has proven very 
effective against many antibiotics.  Chromosomal resistance is the main mechanism of 
widespread resistance to the quinolone antibiotics.  This is achieved through mutations 
that result in altered target enzymes or less permeable cell walls, which may display 
decreased drug uptake or an efflux pump.  This same resistance pattern is seen in the 




     The mechanisms for antibiotic resistance must proliferate throughout the bacterial 
population (and therefore, the patient population) in order for a resistant organism to be 
detected on a clinical level.  Many types of bacteria have short generation times, which 
favor the communication of resistance genes.  Resistance genes usually develop as the 
result of a chance mutation in the transcription or translation of the cell’s DNA during 
replication (“Antimicrobial (Drug) Resistance: Causes”.)  If the mutation leads to 
production of a protein that enacts some form of resistance, the gene that carries the new 
mutation will propagate, as microbes without the resistance will be eliminated by 
antibiotics and only the resistant survivors will reproduce.  A series of mutations may 
alter a group of proteins and work synergistically in resistance and may be passed on in a 
set of genes known as an integron (Goering 481-483.)  This can occur by transcription 
and translation of the new gene, transposons infiltrating DNA, or by horizontal gene 
transfer by plasmids, small pieces of extrachromosomal DNA that are passed on by 
contact (“Antimicrobial (Drug) Resistance: Causes”.)        











3. Specific Organisms 
 The variety and versatility of antibiotic-resistant organisms seen by national and global 
surveillance today is a major concern in both public health and health management 
forums.  One of the earliest recorded resistant organisms was Staphylococcus aureus, 
which became resistant to penicillin in the early 1950’s.  By the 1960’s it was resistant to 
methicillin, and MRSA was first seen in the United States in 1968.  It is now resistant to 
all β-lactams, and is beginning to show resistance to vancomycin (“Antimicrobial (Drug) 
Resistance: MRSA”.)  It is hypothesized that vancomycin resistance may have been 
passed to other bacteria via vancomycin-resistant Enterococci, first reported in the 
1980’s.  VRE alone constitutes approximately one-third of intensive care unit infections, 
and its ability to transmit resistance genes magnifies its threat (“Antimicrobial (Drug) 
Resistance: VRE”.)        
     In community-acquired antibiotic resistant infections, a major concern is multi-drug 
resistant Neisseria gonorrheae.  N. gonorrheae is now resistant to all classes of 
antibiotics except for the cephalosporins, and it is only a matter of time before its 
resistance increases.  In addition, other species of Neisseria can easily become resistant 
as well; characteristically, Neisseria adsorbs DNA and plasmids from other species of 
bacteria particularly well.  Its widespread nature in sexually active populations is cause 
for concern; combined with resistance to almost all available treatments, presents a recipe 
for disaster (“Antimicrobial (Drug) Resistance: Gonorrheae”.)  
     On a global scale, there is much concern about the rise of drug-resistant Tuberculosis. 
Tuberculosis is the leading infectious killer in the world, accounting for approximately 2 
million deaths.  Tuberculosis is now commonly resistant to two of the first-line 
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treatments, rifampin and isoniazid, and may be known as MDR TB.  In addition, XTB is 
resistant to those two antibiotics and most of the second-line treatment options.  Both are 
extremely difficult to treat and can require months or years of combined antibiotic 
therapy (“Tuberculosis”.)  
Within hospitals, Klebsiella species and Pseudomonas aeruginosa are on the rise as 
serious nosocomial infections (“Antimicrobial (Drug) Resistance: Examples”.)  No 
medical center is exempt from the threat of takeover by resistant bacteria.  In fact, in June 
of 2011, at Washington D.C.’s NIH Medical Center, a large medical facility associated 
with the National Institutes of Health, a strange outbreak pattern associated with 
carbapenemase-producing Klebsiella pneumoniae surfaced.  Carbapenemase is a beta-
lactamaze enzyme produced by the bacteria that inactivates carbapenems, penicillins and 
cephalosporins (Queenan.)  The outbreak began with the transfer of one woman who was 
known to carry the resistant Klebsiella to NIH Medical Center’s Intensive Care Unit.  
The woman was accommodated in standard contact isolation precautions, and all patients 
in the ICU were regularly tested with nasal and groin swabs to monitor any potential 
spread; none was noted.  In about a month, the woman recovered and was discharged, 
with no trace of the bacteria in hospital equipment or patients.  Three weeks after the 
former patient was discharged, another patient was discovered to have an infection with 
the same bacteria, and another woman came down with it another week later.  Soon, 17 
more patients fell ill, and genetic sequencing revealed that all patients were infected with 
the same strain (Neergaard.)   
    After this revelation, the hospital adopted more stringent isolation precautions, 
including building an additional wall to further separate the ICU from the rest of the 
Duhamel 14 
 
hospital and not allowing any person who did any kind of work in the ICU to work in any 
other area of the hospital.  All patients regularly underwent more invasive swab testing to 
check for infection.  Hospital workers were tested and never found to be carriers.  Despite 
these additional precautions, at least one patient per week continued to succumb to the 
infection.  Automated disinfection methods that dispensed disinfectant into even the 
smallest crevices of patient rooms were employed, and still the outbreak escaped the ICU 
to infect patients in completely unrelated areas of the hospital.  This prompted the 
construction of a new isolation room and regular testing of all hospital inpatients, and 
still, the outbreak continued until December of 2011.  All seven of the survivors of this 
deadly and concerning outbreak are still carriers of the resistant Klebsiella pneumoniae 
(Neergaard.)   
     This outbreak is particularly alarming because the exact mode of transmission was 
never pinpointed.  Resistance to decontamination methods or infection of the ventilation 
systems are possible mechanisms of spread.  Although the organism was never cultured 
from swabs of healthcare workers’ hands, it is possible that they were carrying it from 
patient to patient on their clothing.  It is also possible that a combination of infection 
mechanisms were implicated, making it almost impossible to control the spread of 
infection.  This outbreak was extremely difficult to contain, and the infection was never 
completely extinguished in the survivors.  These facts pose a very threatening picture of 
the future of antibiotic resistance; this outrageous instance may very soon become a 
normal pattern for resistant outbreaks if new and effective infection control measures are 
not implemented (Neergaard.) 




4. Response and Control 
 The World Health Organization has developed a plan in response to the rise of antibiotic 
resistant microorganisms.  The WHO’s plan emphasizes the importance of a concerted 
effort from policy-makers, medical practitioners, pharmacists, the pharmaceutical 
industry, patients, and the general public to create and uphold policies and practices in 
infection control and responsible use of antibiotics.  The WHO recognizes that 
surveillance, guidance in the making of policies, generation of partnerships, and disease 
prevention and control programs are vital to the success of this plan.  In addition, 
maintenance of quality, reliable supply, appropriate use of antibiotics and laboratory 
testing excellence is a major part of the response to resistance.  Consistent use of 
universal precautions, personal protective equipment, and isolation precautions in the 
healthcare environment are also critical to prevent the spread of infection (“Antimicrobial 
Resistance”, WHO.)  
      New research holds much promise for the development of new antibiotics that will be 
effective against resistant organisms, and is desperately needed in order to regain control 
of the current health situation.  In one Notre Dame study, for example, testing of three 
new cephalosporin-type antibiotics has shown that they interact with penicillin-binding 
protein in MRSA, which is inactivated in cases of resistance, to restore its normal 
function and to allow normal antibiotic action (Gilroy, “NewAntibiotics”.) 
     In reference to the previously-mentioned article concerning oxidized guanine as the 
basis of antibiotic action, additional research in that field revealed potential targets for 
new antibiotics.  When the action of the aminoglycosides was studied, it was found that 
Duhamel 16 
 
this class of drugs induces the incorporation of oxidized guanine into mRNA, which 
results in non-functional proteins that produce more of the hydroxyl radicals, leading to 
greater levels of oxidized guanine in the cell.  The outcome invariably is progressively 
faster cell dysfunction and death (Trafton.)  
     Inquisition into the tactics used by the cell to repair the damage of oxidized guanine, 
such as DNA excision and repair, showed that DNA-destroying double-strand breaks are 
common due to the extent of infiltration of oxidized guanine in the cell.  The cell 
undergoes homologous recombination in an attempt to repair the double-strand breaks, 
providing a new opportunity for antimicrobial action:  inhibition of homologous 
recombination.  Blocking a cell’s repair mechanism will make recovery from the damage 
of oxidized guanine impossible and will, therefore, increase antibiotic effectiveness 
(Trafton.) 
     The CDC also has an action plan in response to antimicrobial resistance with updated 
focus on surveillance, research, prevention and control, and new product development.  
The 2012 Update on “A Public Health Action Plan to Combat Antimicrobial Resistance” 
outlines the goals of improving characterization of drug-resistant infections and 
measuring the impact of antimicrobial drug use, continuing the development and 
implementation of strategies to prevent propagation of resistant infections and misuse of 
antibiotics, increasing research and studies of the emergence of resistant infections and 
the creation of new antimicrobial drugs, and developing new rapid diagnostic tests and 
vaccines.  Within the report, action plans to implement all of these goals are outlined in 
detail and delegated to task forces within the CDC or to other organizations such as the 
FDA.  The development and implementation of such action plans on a worldwide basis is 
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a major factor in a successful response to the newest plague of our world (“Public Health 
Action Plan”).   























  IV. Research Findings 
1. CDC 
      A national surveillance effort by the Center for Disease Control and Prevention has 
amassed data representative of trends and patterns seen in MRSA on a countrywide scale. 
Each year a population sample consisting of  14,000 to 20,000 individuals from 
California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New York, Oregon, 
and Tennessee was selected and monitored with standardized case reports to provide 
nationally representative data.  
     In 2005, the surveillance population consisted of 16,489,254 people from the above-
mentioned states.  Of the total, 1,601 cases were found to be healthcare-associated, 
hospital-onset, meaning that MRSA was cultured on or after the fourth day of 
hospitalization.  From this representation, the national estimate of cases of MRSA with 
hospital-onset was 29,311, accounting for 2.64% of the overall estimated 111,345 
healthcare-associated and community-associated cases.  The incidence rate was 9.89 
cases per 100,000 population.  
     In 2006, the population consisted of 14,954,451 individuals from the same states, and 
the number of hospital-onset cases was 1,353.  The national estimate based on this 
distribution was 27,309 (2.50% of 108,345 overall cases) with an incidence of 9.03 cases 
per 100,000 population.  In 2007, the population was 16,968,233 and 1,402 hospital-onset 
cases were reported.  This was adjusted to 25,356 (2.47% of 102,672 overall cases) with 
an incidence of 8.41 cases of MRSA per 100,000 population.   
In 2008, the population was 18,300,643 persons, with 1,298 hospital-onset cases. 
The adjusted estimate was 21,840 (2.28% of 95,872 overall cases) with incidence of 7.18 
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per 100,000 population.  In 2009, the population was 19,311,576, and 1,198 hospital-
onset cases were reported.  The national estimate was 19,235 (2.14% of 89,867 cases) 
with an incidence of 6.27 cases per 100,000 population.  In 2010, the population was 
19,154,389 people with 970 cases of hospital-onset MRSA.  The nationally adjusted 
estimate was 15,744 (1.92% of 82,042 cases) with an incidence of 5.10 cases per 100,000 
population.   
     The data from the years 2005-2010 was graphed and linear regression was performed 
to visualize the significant decline in number of cases of MRSA over those years. The 
mean number of cases over this time period is 1304, and the standard deviation is 211.  
The graph is consistent with an overall steady decrease in the number of cases of MRSA 





When this was translated to numbers representing actual estimates for the entire 
nation, the following linear correlation was found.  The mean number of cases is 23,088 
and the standard deviation is 5095.  Over the five years studied, the number of cases 











2.  NH Department of Health and Human Services 
 
    The State of New Hampshire’s Department of Health and Human Services provided its 
2009 Report of NH Healthcare-associated Infections, which gives case data on all 
healthcare-associated infections that occurred at all hospitals in New Hampshire.  Darlene 
Morse, RN, a member of the Bureau of Infectious Disease Control, stated that this is the 
most comprehensive data about infection rates available at the state level, and that rates 
of specific infections are not reportable to the State Health Department in the State of 
New Hampshire.  Reporting of healthcare-associated infection rates will connect the 
broad national data to reports from individual seacoast area hospitals and serve as a frame 
of reference with respect to hospital size and infection rate.  
     Throughout 2009, in all 26 New Hampshire acute care hospitals, only 134 healthcare 
associated infections (as defined above by the CDC) were reported, 26% fewer infections 
than the expected 180 defined by national rates.  Of those 134 infections, 110 were 
surgical-site infections, and 24 were associated with central lines (NH Healthcare 
Infections Report.)  Data gathered from voluntarily participating hospitals selected from 
those mentioned in the report show that much less than 10% of these infections were due 
to MRSA.   
     Within the state's report, data is represented as the actual numbers of cases recorded 
and a Standardized Infection Ratio, which represents the comparison of the number of 
cases occurred to the expected number of cases.  Thus, an SIR of one means that the 
number of actual and expected cases are equal, and an SIR of less than one means that 
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less cases than expected were recorded, and an SIR greater than one means that more 
cases than expected occurred (NH Healthcare Infections Report.) 
     Of the 26 hospitals recorded, six reported significantly lower numbers of infections 
than expected, and the rest were consistent with the predicted number of infections.  The 
data table and graphical representation of results is included below.  This information is 
important to understand before reviewing the findings of this study because it provides a 
context for the following analysis and a significant consideration in the analysis of rates 
of antibiotic-resistant infection.  
     The national data represent healthcare-associated cases of MRSA, meaning that the 
bacteria were acquired during hospitalization, and the state's data represent healthcare-
acquired infections as well.  Data acquired from participating hospitals represents all 
isolates, though not all isolates cause disease.  It can, therefore, be surmised that the data 
from hospitals provides a more detailed analysis of the incidence of MRSA in the general 
population.  National data is representative of the widespread incidence, the State of New 
Hampshire's data is evidence of the effects of this antibiotic-resistant bacteria, and the 
hospital reports present literal numbers of isolates found within their respective 
healthcare communities.  








3. Local Hospital #1 
     Data from a small, local 100-bed hospital originates from yearly case reports collected 
by the infection control department and compiled based on culture isolates from the 
hospital only, and thus, represents an inpatient population.  In 2006, 60 cases of MRSA 
were reported.  In that year, 805 isolates of various species were screened for resistance 
to various antibiotics with varying levels of resistance resulting.  In this hospital, MRSA 
represented 7.45% of these cases.  In 2007, 91 cases of MRSA were isolated, 9.3 percent 
of 979 various isolates.  In 2008, 133 cases of MRSA were found among 1089 isolates, 
representing 12.21% of isolates.  In 2009, 121 cases of MRSA were reported from 1086 
isolates, 11.14%.  In 2010, 82 MRSA isolates were cultured from 1089 total isolates, 
7.53%.  In 2011 78 MRSA isolates were found among 1185 total isolates, 6.58%.   
     The graphical representation of these data shows a wide distribution of cases with a 
mean of 94 cases per year and a standard deviation of 28.  Linear regression shows a very 
mild slope representing no significant increase or decrease in number of cases of MRSA 
due to the wide distribution of data points.  The actual number of cases increased from 60 
in 2006 to 78 in 2011, with very little significant change.  The percentage of isolates that 
were found to be MRSA actually decreased from 7.45% to 6.58%, meaning that although 
slightly more cases were recorded, they represent less of all bacterial isolates from that 



















4. Local Hospital #2 
     A larger (330-bed) local hospital also submitted infection control and epidemiology 
data in the same format as the 100-bed hospital.  At this hospital in 2011, 5891 isolates of 
various organisms were screened for resistance to varying antibiotics.  Of the 5891 
isolates, 507 tested positive for Staphylococcus aureus, and 235 of those also tested 
positive for MRSA, 3.99% of all isolates.  Although 46% of all S. aureus isolates were 
MRSA, MRSA still represented only 3.99% of all isolates tested.  
     The following graphical representations show that although MRSA represented a very 
small percentage of bacterial isolates, it represented almost half of all Staphylococcus 
aureus infections.  This statistic is of concern because it suggests that more and more 





















     The threat of antibiotic resistance for the modern healthcare industry is a prominent 
and menacing reality.  It is true that current medical technology is struggling to keep up 
with the many ways in which bacteria evade the strongest developed drugs and 
chemicals; they thrive in hidden corners of our bodies, environments, and even medically 
sterile locations.  No place, person, race, sex, belief system, or amount of money can 
protect us; bacteria do not discriminate or spare anyone in their path. The only truly 
effective weapons we possess are our innate immune systems and the power of 
knowledge.   
     The research performed on national, state, and individual hospital levels has shown 
that our knowledge and organization of infection control protocols and measures has been 
effective in fighting one of the most prominent organisms, methicillin resistant 
Staphylococcus aureus.  Though national rates of infection are still in the tens of 
thousands, there is a definite quantifiable decrease in the numbers of infections recorded 
over five years.  State records reveal that 23% of hospitals had significantly lower 
infection rates than expected, and none significantly exceeded the expectation.  
Individual hospitals report steady low numbers of MRSA isolates over the past few years, 
although more cases of S. aureus infections are becoming resistant.  The information 
from all sources is essentially in agreement.  
     Though antibiotic resistance is easily perpetuated across species of bacteria and 
absolute resistance is a reality in XTB and Vancomycin resistant Enterococci and Staph 
aureus, we gain an advantage by following standard precautions of infection prevention 
and improving education and compliance with antibiotic therapy.  It will remain a tight 
Duhamel 28 
 
race as bacterial and human species coevolve, but the promise of new mechanisms to 
fight infection keep hope of regaining control alive.  
      
 
